Although we recognize the dangers of giving a nonmyleoablative chemotherapy and IL-2 to patients with recurrent brain tumors ( em e.g /em ., capillary leak syndrome and thrombocytopenia), we are motivated by our encounter treating metastatic tumors to the brain in individuals with melanoma using TILs along with IL-2 following Continue Reading